NCT00536341 - Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2013

Study Completion Date

November 30, 2016

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

lenalidomide

2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6

DRUG

Rituximab

375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6

DRUG

Fludarabine

25 mg/m2 on Days 1, 2, and 3

Trial Locations (6)

Center for Cancer and Blood Disorders, Bethesda

National Capital Clinical Research Consortium, Bethesda

South Carolina Oncology Associates, PA, Columbia

Florida Hospital Cancer Institute, Orlando

Florida Cancer Specialists, Fort Myers

Tennessee Oncology, PLLC, Nashville